Introduction {#sec1-1}
============

Diabetes mellitus is prevalent worldwide, and Saudi Arabia ranks as the second highest in the Middle East, and the seventh in the world for the rate of diabetes (34.1% in males and 27.6% in females).\[[@ref1][@ref2]\] Diabetic peripheral neuropathy (DPN) is a nerve damaging disorder caused by diabetes and is related to duration and degree of glycemic control.\[[@ref3]\] Neuropathy results in significant morbidities such as a pain, loss of sensation, foot ulcers, gangrene, and amputations.\[[@ref4][@ref5]\] The prevalence of DPN internationally ranges between 26.4% and 35.78% and nationally between 19.9% and 35%.\[[@ref6][@ref7][@ref8]\] The foot ulceration is not only the most common complication of neuropathy but also among the preventable diabetes complications.\[[@ref9]\] The prevalence rate of diabetic foot in the world is about 4.6--12%.\[[@ref10][@ref11][@ref12]\] In the literature, the risk of DNP was found to be associated with age, duration of DM, glycemic control (high level of HbA1c), gender, and smoking.\[[@ref13]\] The aim of this study was to assess the prevalence of painful DPN and its associated risk factors in patients with diabetes mellitus attending primary healthcare (PHC) in AL Madinah city, Saudi Arabia.

Materials and Methods {#sec1-2}
=====================

This cross-sectional study was carried out in the PHCs in AL Madinah city. Twelve centers were selected randomly from a total of 40 centers in the city. Thirty-one diabetic patients were selected by systematic random sampling from each health center to get a total sample of 430 patients. Data was collected 5/7 days for 1 week. Patients were included if they met all the following criteria: aged ≥18 years; presenting at an outpatient clinic; current diagnosis of diabetes mellitus type 1 (duration ≥5 years) or type 2 (any duration); no other type of neuropathic pain of non-diabetic origin. Gestational diabetes was excluded. Diagnosis of diabetes mellitus was based on the American Diabetes Association (ADA) guidelines (random blood sugar \>200 mg/dL or fasting blood sugar \>126 mg/dL).\[[@ref14]\]

The first part of the questionnaire included questions on the sociodemographic characteristics, comorbidities, duration, and type of diabetic mellitus. The second part included the validated Douleur Neuropathique-4 (DN4), which was used to identify the presence of painful DPN and is a brief 10-item questionnaire.\[[@ref15]\] The first seven items of the DN4 based on patient\'s interview and the final three items are based on physical examination of sensory function. All questions were answered either "yes" or "no." "Yes" answer was given 1 point and "No" answer was given zero. The total score ranges from 0 to 10 and a score of 4 or more is considered the cutoff point for the diagnosis of neuropathic pain. The original version was validated by Bouhassira *et al*. (2005) and the Arabic version used in this study was validated by Harifi *et al*. (2013).\[[@ref15][@ref16]\] The first three questions investigated the characters of pain (burning, painful cold, and electric shocks), the next four questions investigated the symptoms associated with the pain (tingling, pins and needles, numbness, and itching). The next two questions investigated hypoesthesia to touch and hypoesthesia to prick. The last question investigated if the pain be caused or increased by brushing. The last measure of hemoglobin A1c (HbA1c) for each participant was taken from the hospital records.

This study protocol was approved by the ethical committee of the Institutional Review Board in Al-Madinah. Objectives and benefits of the study were explained to the participants. Participant\'s confidentiality and anonymity were assured. Signed consent was obtained from those who agreed to participate.

Statistical analysis was carried out by using Statistical Package for the Social Sciences (SPSS^®^) software (version 20). Descriptive statistics was employed to obtain frequencies, mean, and standard deviations. Chi-square test was employed to assess association between DPN and categorical data. The accepted level of significance was set below 0.05 (*P* \< 0.05).

Results {#sec1-3}
=======

The majority were female (54.7%), aged between 46 and 65 years (44%), had type 2 diabetes mellitus (74.9%), and had family history of DM (61.2%). Most of the participants had uncontrolled HA1c (82.1%). The most common reported comorbidity was hypertension (45%) \[[Table 1](#T1){ref-type="table"}\].

###### 

Sociodemographic characteristics of the participants

  Variable                 *n*   Percentage
  ------------------------ ----- ------------
  Age (years)                    
   ≤25                     66    15.3
   26-45                   79    18.4
   46-65                   189   44.0
   \>65                    96    22.3
  Gender                         
   Male                    195   45.3
   Female                  235   54.7
  Type of DM                     
   Type 1                  108   25.1
   Type 2                  322   74.9
  Family history of DM           
   Yes                     263   61.2
   No                      167   38.8
  Duration of DM (years)         
   \<5                     131   30.5
   6-10                    109   25.3
   11-20                   115   26.7
   \>20                    75    17.4
  HA1c status                    
   Controlled HA1c         77    17.9
   Un-controlled HA1c      353   82.1
  Smoking                        
   Yes                     96    22.3
   No                      334   77.6
  Foot ulcer               68    15.8
  History of amputation    25    5.8
  Hypertension             197   45
  Hyperlipidemia           123   28.6
  Cardiac diseases         43    10
  Asthma                   34    7.9
  Stroke                   29    6.7
  Thyroid diseases         38    8.8
  Renal diseases           21    4.9
  Vision loss              23    5.3

The prevalence of DPN was 30.1% in type 2 diabetic patients and 25.9% in type 1diabetic patients with an overall prevalence of 29.1%.

The most common symptoms and signs of pain were tingling (26.7%), hypoesthesia to touch (23.3%), and pins and needles (23%) \[[Table 2](#T2){ref-type="table"}\].

###### 

Symptoms and signs of DPN pain among diabetic patients

  Symptoms and signs         *n* (%)
  -------------------------- -------------
  Burning pain               79 (18.4%)
  Painful cold               50 (11.6%)
  Electric shocks            39 (9.1%)
  Tingling                   115 (26.7%)
  Pins and needles           99 (23%)
  Numbness                   96 (22.3%)
  Itching                    41 (9.5%)
  Hypoesthesia to touch      100 (23.3%)
  Hypoesthesia to pinprick   77 (17.9%)
  Pain on brushing           43 (10%)

[Table 3](#T3){ref-type="table"} shows factors associated with DPN. The prevalence of DPN increased significantly with increased in the age and all the age groups had higher prevalence of DPN compared to the age group 18--25 years (*P* \< 0.05). The prevalence of DPN increased significantly with increased in the duration of DM (*P* \< 0.05). Patients with uncontrolled A1c had higher prevalence of DPN (39.4%) compared to patients with controlled A1c (14.9%) (OR = 3.7, 95% CI 2.30--6.0).

###### 

Factors associated with DPN among diabetic patients

  Variable                 Diabetic Peripheral Neuropathy   Odds Ratio   95% CI   *P*          
  ------------------------ -------------------------------- ------------ -------- ------------ ---------
  Gender                                                                                       
   Male                    60 (30.8)                        135 (69.2)   1.2      0.7 - 1.7    0.274
   Female                  65 (27.7)                        170 (72.3)                         
  Age (years)                                                                                  
   18-25                   8 (12.1)                         58 (87.9)    Ref                   
   26-45                   16 (20.3)                        63 (79.7)    6.4      2.7 - 14.8   \<0.001
   46-65                   56 (29.6)                        133 (70.4)   3.5      1.7 - 6.8    \<0.001
   \>65                    45 (46.9)                        51 (53.1)    2.1      1.2 - 3.4    0.004
  Smoking                                                                                      
   Yes                     32 (33.3)                        64 (66.7)    1.3      0.7 - 2.1    0.179
   No                      93 (27.8)                        241 (72.2)                         
  Type of DM                                                                                   
   Type 1                  28 (25.9)                        80 (74.1)    0.8      0.4 - 1.3    0.241
   Type 2                  97 (30.1)                        225 (69.9)                         
  Duration of DM (years)                                                                       
   \<5                     17 (13.0)                        114 (87.0)   Ref                   
   6-10                    22 (20.2)                        87 (79.8)    6.9      3.4 - 13.6   \<0.001
   11-20                   48 (41.7)                        67 (58.3)    4.1      2.1 - 7.7    \<0.001
   \>20                    38 (50.7)                        37 (49.3)    1.4      0.7 - 2.5    0.228
  HA1c Level                                                                                   
   Controlled HA1c         27 (14.9)                        154 (85.1)                         
   Un-Controlled HA1c      98 (39.4)                        151 (60.6)   3.7      2.3 - 6.0    \<0.001

[Table 4](#T4){ref-type="table"} shows the association between comorbidities and DPN. All comorbidities were associated significantly with DPN: hypertension (OR = 2.1, 95% CI1.47--3.44), asthma (OR = 2.3, 95% CI1.15--4.75), thyroid diseases (OR = 2.1, 95% CI 1.08--4.18), cardiac diseases (OR = 2.6, 95% CI1.37--4.92), stroke (OR = 2.4, 95% CI1.14--5.21), and renal diseases (OR = 4.3, 95% CI1.73--10.67).

###### 

Comorbidities associated with DPN among diabetic patients

  Comorbidities      Diabetic Peripheral Neuropathy   Odds Ratio   95% CI   *P*         
  ------------------ -------------------------------- ------------ -------- ----------- ---------
  Hypertension                                                                          
   Yes               75 (38.1)                        122 (61.9)   2.2      1.4 - 3.4   \<0.001
   No                50 (21.5)                        183 (78.5)                        
  Asthma                                                                                
   Yes               16 (47.1)                        18 (52.9)    2.3      1.1 - 4.7   0.016
   No                109 (27.5)                       287 (72.5)                        
  Thyroid diseases                                                                      
   Yes               17 (44.7)                        21 (55.3)    2.1      1.1 - 4.1   0.023
   No                108 (27.6)                       284 (72.4)                        
  Cardiac diseases                                                                      
   Yes               21 (48.8)                        22 (51.2)    2.5      1.3 - 4.9   0.003
   No                104 (26.9)                       283 (73.1)                        
  Stroke                                                                                
   Yes               14 (48.3)                        15 (51.7)    2.4      1.1 - 5.2   0.019
   No                111 (27.7)                       290 (72.3)                        
  Renal diseases                                                                        
   Yes               13 (61.9)                        8 (38.1)     4.3      1.7-10.6    0.001
   No                112 (27.4)                       297 (72.6)                        

Discussion {#sec1-4}
==========

The prevalence of DPN was 29.1% in this study, which was higher than a worldwide estimate of DPN prevalence among diabetics (8.1 -- 12.2%).\[[@ref17]\] In Saudi Arabia, a prevalence of 65.3% has been previously reported for painful DPN in a nationally representative diabetic population in 2010.\[[@ref18]\] In other Middle East countries, the prevalence rates of painful DPN were 61.3%, 57.5%, 53.9%, and 37.1% for Egyptian, Jordanian, Lebanese, and Gulf States population, respectively.\[[@ref19]\] Similar high prevalence was found in India (69%).\[[@ref20]\] Duration of diabetes showed significant association with DPN in this study. It was reported in the literature that the prevalence of neuropathy increases after 5 years of the diagnosis of DM.\[[@ref21]\] So it is imperative to perform the neurological testing in the laboratory and scoring systems should also be included. It is better to educate patients to examine their foot at least annually and the early detection of DN makes the healthcare professionals and patients to initiate the preventive measures and can evaluate the therapeutic options. Previous studies found that the prevalence of DNP was higher among females.\[[@ref22]\] However, the current study did not find such association and this finding is consistent with a previous study by Popescu *et al*. (2015).\[[@ref23]\] This study found that prevalence of DNP increased by age. This finding is consistent with the previous studies.\[[@ref23][@ref24][@ref25]\] In the current study, we found a significant association between the HbA1c levels DNP. Similar finding was reported in the previous studies.\[[@ref23][@ref26]\] This study found a significant association between DNP and comorbidities such as hypertension, asthma, thyroid diseases, cardiac diseases, stroke, and renal diseases. A previous study found significant association between DNP and chronic kidney disease but not with hypertension.\[[@ref23]\]

The strength of this study is apparent in its large and representative sample size and by using a validated tool. However, several limitations of this study warrant attentions. First, the cross-sectional nature of this study design limits the inference of causal relationship between correlates and DPN. Therefore, our findings need to be confirmed in prospective studies. Second, the diagnosis of DPN was based on a combination of decreased sensation and neuropathic sensory symptoms, without nerve conduction test.

In conclusion, the prevalence of DPN was 30.1% in type 2 diabetic patients and 25.9% in type 1diabetic patients with an overall prevalence of 29.1%. DNP was associated with age duration of DM and uncontrolled HbA1c. PHC physicians treating diabetes should be more aware of the importance of screening for DPN and the treatment plan.
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